AbbVie announced it will acquire Apogee Therapeutics, a clinical-stage biotech company, for approximately $10.9 billion. This acquisition gives AbbVie control over Apogee's diverse pipeline of clinical-stage candidates focused on inflammatory and immunological diseases. The deal highlights AbbVie's strategic expansion in these therapeutic areas and could enhance its product offerings in the future. Apogee's stock surged following the announcement, reflecting investor optimism about the acquisition.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
